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Abstract
Background: Infection with dengue viruses (DENV) leads to a spectrum of disease outcomes. The pathophysiology of severe
versus non-severe manifestations of DENV infection may be driven by host responses, which could be reflected in the
transcriptional profiles of peripheral blood immune cells.
Methodology/Principal Findings: We conducted genome-wide microarray analysis of whole blood RNA from 34 DENV-
infected children in Nicaragua collected on days 3–6 of illness, with different disease manifestations. Gene expression
analysis identified genes that are differentially regulated between clinical subgroups. The most striking transcriptional
differences were observed between dengue patients with and without shock, especially in the expression of mitochondrial
ribosomal proteins associated with protein biosynthesis. In the dengue hemorrhagic fever patients, one subset of
differentially expressed genes encode neutrophil-derived anti-microbial peptides associated with innate immunity. By
performing a meta-analysis of our dataset in conjunction with previously published datasets, we confirmed that DENV
infection in vivo is associated with large changes to protein and nucleic acid metabolism. Additionally, whereas in vitro
infection leads to an increased interferon signature, this was not consistently observed from in vivo patient samples,
suggesting that the interferon response in vivo is relatively transient and was no longer observed by days 3–6 of illness.
Conclusions/Significance: These data highlight important differences between different manifestations of severity during
DENV infection as well as identify some commonalities. Compilation of larger datasets in the future across multiple studies, as
we have initiated in this report, may well lead to better prediction of disease manifestation via a systems biology approach.
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Introduction
Infection by the four serotypes of dengue virus (DENV 1–4) can
lead to outcomes ranging from asymptomatic infection to
hemorrhagic fever and shock [1]. While many epidemiological
risk factors have been identified for the development of the severe
forms of disease [2], dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS), there is still much uncertainty as to the
molecular mechanisms underlying pathogenesis [1,3,4]. Identify-
ing signatures of host genome-wide transcriptional patterns can be
a tool for biomarker discovery as well as for understanding
molecular mechanisms and pathophysiological signatures of
disease states. This approach has been applied in cancer biology
[5] and infectious diseases [6,7]. Recently, there have been several
reports of expression profiling studies in DENV-infected patients
[8,9,10,11] and macaques [12]. Other groups have monitored
gene expression in cell lines and primary cells infected with DENV
in vitro [13,14,15]. By integrating results from in vitro studies as well
as multiple in vivo studies from different field sites, it may be
possible to assemble a comprehensive picture of DENV-host
interactions that lead to different disease outcomes.
The four DENV serotypes have been reported to exhibit
distinct clinical characteristics [16,17,18]. It is currently unknown
whether different serotypes are associated with distinct transcrip-
tional profiles from peripheral blood. Unlike Southeast Asia where
all DENV serotypes circulate simultaneously, at our study site in
Nicaragua, one serotype tends to predominate each dengue
season [18]. In 2003, when this study was conducted, 87% of the
isolated viruses were DENV-1 serotype. To our knowledge, this is
the first reported transcriptional profiling study of predominantly
DENV-1-infected patients in the Americas rather than Southeast
Asia.
www.plosntds.org 1 June 2010 | Volume 4 | Issue 6 | e710
The goal of our study was to conduct a transcriptional profiling
analysis of pediatric patients from Nicaragua with a predominantly
DENV-1 infection and to compare our results with Southeast
Asian studies with mixed serotype infections. We find that there is
a distinct molecular profile between Nicaraguan dengue patients
with shock relative to patients with DHF, and a more muted
difference between DF patients and patients with DHF. We also
conducted a microarray ‘meta-analysis’ to compare the dataset
from Nicaraguan patients with existing dengue expression
profiling datasets to identify common themes and differences.
Materials and Methods
Study design and clinical definitions
A cross-sectional study was conducted in the Hospital Infantil
Manuel de Jesu´s Rivera (HIMJR), the national pediatric
reference hospital, in the capital city of Managua, Nicaragua,
from September 2003 to February 2004, which represents the
2003 dengue season (see Supplemental Methods). Enrollment
criteria consisted of hospitalized patients younger than 15 years of
age who completed the informed consent and assent process and
who presented with acute febrile illness and two or more of
the following symptoms: headache, retro-orbital pain, myalgia,
arthralgia, rash, and hemorrhagic manifestations. Subjects
reflected the gender, age, and ethnic composition of the local
pediatric population. A standardized questionnaire was admin-
istered to collect demographic and clinical information at
admission, and clinical data during hospitalization was prospec-
tively collected using standardized forms that were completed and
verified via chart review. Venous blood was drawn for clinical
tests and serological, virological and molecular biological dengue
diagnostic assays when patients presented to the Infectious
Diseases Unit, daily during hospitalization, at the time of
discharge, and when possible approximately two weeks after
symptom onset (convalescent sample). Venous blood was
collected in PAXgene tubes for RNA analysis at presentation,
every other day during hospitalization, and when possible at
convalescence. We selected samples from 34 patients for
microarray analysis who presented between days 3-6 of illness.
Patients were classified according to the 1997 World Health
Organization classification scheme as dengue fever (DF), DHF, or
DSS [19].
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Written informed consent was
obtained from parents or legal representatives authorizing the
participation of their children in the study and assent was obtained
from children greater than 5 years old. This study was approved
by the University of California, Berkeley Committee for the
Protection of Human Subjects, the Ethical Review Committee of
the Centro Nacional de Diagno´stico y Referencia (CNDR) of the
Nicaraguan Ministry of Health, and the Institutional Review
Board of the HIMJR.
Microarray processing and data analysis
Samples were drawn into PAXgene tubes (BD, Franklin Lakes,
NJ) to maintain RNA integrity and provide a snapshot of in vivo
blood expression while minimizing time and manipulation
variations (see Supplemental Methods). RNA was then amplified
using the Amino Allyl MessageAmp II aRNA Amplification Kit
(Ambion). A reference consisting of an equal quantity of amplified
RNA from a pool of RNA extracted from PBMCs of 5 healthy
individuals was labeled with Cy3 dye and hybridized against the
Cy5-labeled controls on Human Exonic Evidence-Based Oligo-
nucleotide (HEEBO, Invitrogen) microarrays printed in-house at
the UCSF Center for Advanced Technologies. This oligonucle-
otide set (44,544 70mer probes) was designed using a transcrip-
tome-based annotation of exonic structure for genomic loci
(http://www.microarray.org/sfgf/heebo.do). Typically one micro-
array was performed for each patient sample and the quality of the
image was checked by using the HEEBO quality assessment
graphs using the Bioconductor package. Microarrays that were of
poor quality (high background, low foreground) were repeated.
Two main strategies were used to identify related subgroups of
transcripts and patient subgroups. First, we used unsupervised
approaches such as hierarchical clustering and principal compo-
nent analysis (PCA) for classification of transcripts and patients;
this does not utilize clinical information from the patients, and sub-
groups are identified based purely on transcriptional profiling data
(see Supplemental Methods). Second, patients were divided into
subgroups (DF, DHF, and DSS) based exclusively on clinical
information, and gene expression analysis was focused on
identifying groups of genes that were differentially expressed
significantly between pre-defined clinical groups (see Supplemental
Methods). This type of supervised comparison was used to identify
genes that were significantly up-regulated in DF, DHF and DSS
patient samples relative to convalescent patient samples. This
supervised approach was also used to identify candidate genes
over-represented in patient groups by multi-class SAM analysis
(see below).
Quantitative qRT-PCR
Reverse transcription was performed with 100 ng of the
RNA samples from the 34 individuals and Superscript
III (Invitrogen). Quantitative RT-PCR (qRT-PCR) of the samples
was performed in triplicate using Taqman probes (Defensin
alpha 1 (Hs00234383_m1), Lactotransferrin (Hs00158924_m1),
CD14 (Hs00169122_g1), PRAM1 (Hs00259796_m1), vezatin
(Hs00250257_m1), ZNF600 (Hs01650984_g1), ZNF91
(Hs00602754_mH), EIF-1a (Hs00796778_s1)) and kit (Applied
Biosystems) according to the manufacturer’s instructions on a Step
One Plus real-time PCR system (Applied Biosystems). Samples
with cycle thresholds (Ct) values of .36 cycles for a given probe
were considered undetectable (ud). Ct values were then normal-
ized to the value of a housekeeping gene (HPRT), and data is
presented as a ratio to HPRT.
Author Summary
Dengue is a widespread viral disease for which over 3
billion people are at risk. There are no drug treatments or
vaccines available for this disease. It is also difficult for
physicians to predict which patients are at highest risk for
the severe manifestations known as dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS). We used
genome-wide transcriptional profiling analysis to study
peripheral blood responses to dengue among patients
from Nicaragua. We found that patients with severe
manifestations involving shock had very different tran-
scriptional profiles from dengue patients with mild and
moderate illness. We then compared our results with other
microarray experiments on dengue patients available from
public databases and confirmed that dengue is often
associated with large changes to the metabolic processes
within cells. This approach could identify prognostic
markers for severe dengue as well as provide a better
understanding of the pathophysiology associated with
different grades of disease severity.
Gene Expression Profiling Dengue in Nicaragua
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Meta-analyses of dengue expression profiling datasets
For studies with corresponding Genepix or Affymetrix CEL
files available in a public repository, the original files were
downloaded and processed using a standardized workflow (see
Supplemental Methods). For studies that did not have original
intact array files available, we relied on the authors’ preprocessed
data. Expression values were log2 transformed and arrays were
median centered. Groups of arrays within each study were
collapsed by averaging, and all of the arrays were also ‘‘zero’’-
transformed by a set of healthy/convalescent samples (for in vivo
studies) or uninfected/heat-inactivated virus-treated samples (for
in vitro studies) within each study. Data was then mapped to
Human HGNC gene ID’s (see Supplemental Methods). Finally,
all the columns in the integrated dataset were standardized
(z-score transformed).
Pathway analysis/statistical methods
Filtered datasets were also analyzed for statistically significant
genes using the Statistical Analysis of Microarray (SAM)
software version 2.23A [20]. SAM was used for supervised
two-way comparisons as well as multi-class analysis. Genes
identified by clustering or SAM analysis were visualized using
the Treeview (http://rana.lbl.gov/EisenSoftware.htm). Gene
ontology and pathway analyses were performed using PAN-
THER (http://www.pantherdb.org/) [21]. Gene lists were
introduced into PANTHER along with a background gene list
representing all of the genes present in the human genome.
Statistical comparisons of qRT-PCR data by the non-paramet-
ric two-tailed Mann-Whitney test was conducted using PRISM
(Graphpad).
Results
Research subject characteristics
We analyzed samples collected from confirmed DENV-infected
individuals in Nicaragua recruited during the dengue season of
2003, with predominantly DENV-1 in circulation [17]. PAXgene
tubes were analyzed from 34 individuals with samples collected
between days 3–6 of illness on the day of admission (Table 1). All
of the individuals were hospitalized in the Infectious Disease Unit
of the Hospital Infantil Manuel de Jesu´s Rivera (HIMJR). Twenty
patients were classified as dengue fever (DF) according to the
traditional WHO criteria [19]. Six patients developed DHF, and
eight patients developed DSS (Table 1). Convalescent samples
from six patients (two with DF, one with DHF, three with DSS)
were also collected for analysis 14–19 days after onset of
symptoms, after they were discharged from the hospital.
Overall gene expression profiles correlate with clinical
status
We used hierarchical clustering to determine whether the
molecular profiles alone could distinguish between patients with
different clinical manifestations. The unsupervised organization of
the samples based on gene expression levels of all available genes
post-filtering (n = 8,485) led to the segregation into primarily three
groups (Figure 1A). The first group (horizontal bar 1) contained
most of the DHF patients (4/6, with one patient closely associated)
and the majority of the DF patients (13/20). The second group
(horizontal bar 2) included almost all (7/8) of the DSS patients.
The third group (horizontal bar 3) included all (4/4) of the healthy
controls and most (5/6) of the convalescent samples.
Table 1. Clinical features of confirmed dengue cases by disease classification.
Variable
DF
(n =20)
Mean (range)
DHF
(n =6)
Mean (range)
DSS
(n=8)
Mean (range)
Age, yrs 7 (9m-12) 12 (7–14) 7 (10m-14)
Platelet nadir, cells/ml 77,600 (18,000–148,000) 60,000 (39,000–81,000) 49,000 (24,000–65,000)
Leucocytes nadir, cells/ml 4,065 (1,500–9,100) 3,683 (1,900–6,500) 4,337 (1,800–8,700)
Hct, nadir, % 33.3 (25–39) 34.5 (30–38) 31.8 (26–37)
Hct peak, % 37.6 (33–47) 40.2 (36–43) 36.6 (27–45)
Hct discharge, % 35.6 (29–44) 36.7 (30–42) 33.4 (27–40)
Days of illness at time of sample collection 4.2 (3–6) 4.2 (3–5) 4.6 (3–6)
Variable n (%) n (%) n (%)
Gender male 10 (50) 3 (50) 7 (88)
Primary infection 4 (20) 2 (33) 2 (25)
Secondary infection 16 (80) 4 (67) 6 (75)
Thrombocytopenia (,100,000 cells/ml) 16 (80) 6 (100) 8 (100)
Plasma leakage* 3 (15) 6 (100) 6 (75)
Narrow pulse pressure 0 0 3 (38)
Hypotension 0 0 5 (63)
Slow capillary refill (.2 sec) 1 (5) 2 (33) 3 (38)
Cold clammy skin 3 (15) 3 (50) 5 (63)
*Elevated hematocrit for age or when compared to discharge Hct or other signs of plasma leakage (pleural effusion, ascites).
doi:10.1371/journal.pntd.0000710.t001
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We then applied Principal Component Analysis (PCA) to
identify internal structures within the dataset. The variance
explained by the principal components when PCA is applied is
shown in Figure S1. The first two components (PCA1 and PCA2)
explain much more variance than the other components. We then
projected each patient sample onto these two components
(Figure 1B) and observed that the majority (.75%) of the DSS
patients clustered together, but were separate from the majority
(.75%) of DF and DHF patients. We also observed that the values
for PCA2 appeared to separate the DSS samples from the DF and
DHF samples more distinctly than PCA1, and this was statistically
significant (Figure S1B). We then identified 61 genes (from 66 data
spots) that contributed towards the top 5% of the positive variance
explained by PCA2 (Figure S1C). When we reclustered the patient
samples based on the expression patterns of these 61 genes, we
found that almost all of the DSS patients clustered together (7/8),
while the majority of the DF and DHF patients also clustered
together (Figure 1C). We also identified the top 5% of genes
(n = 90, from 93 spots) that were positively correlated with PCA2
(n= 1832 at a false discovery rate of 5%), and reclustering with
these 90 genes produced a similar result (Figure S1D).
To identify which biological processes were over-represented in
the set of 61 genes, we performed gene ontology (GO) analysis.
Most of the genes that were associated with shock appear
unrelated to the immune response, while genes involved in
‘protein biosynthesis’ (n = 11) and ‘protein metabolism and
modification’ (n = 21) were significantly enriched (P,0.05) in this
list (Table S1). A large number of mitochondrial ribosomal
proteins are also found on this list, reflecting an enrichment of
‘ribosomal proteins’ (n = 9, P= 2.7E-04) and of ‘nucleic acid
binding’ (n = 16, P= 2.56E-02) molecular functions. GO analysis
of the 90 genes representing the top 5% of genes correlated with
PCA2 also produced similar results (Figure S1E).
Identifying differentially expressed genes through
supervised comparisons
We next conducted supervised two-way comparisons using the
statistical analysis of microarrays (SAM) method [20] to compare
expression of transcripts between the acute (DF: n= 20; DHF:
n= 6; DSS: n= 8) and convalescent samples (n = 6). Although
there were not sufficient convalescent samples to make autologous
comparisons, we identified 964 genes that were differentially
expressed (711 up-regulated, 253 down-regulated) in acute DF
samples compared to all of the convalescent samples (Table S2),
550 genes that were differentially expressed (494 up-regulated, 56
down-regulated) in acute DHF acute samples (Table S3) and 1203
genes that were differentially expressed (878 up-regulated and 325
down-regulated) in DSS acute samples (Figure 2A, Table S4). A
large number of genes that were up-regulated during acute illness
relative to convalescence (n = 310) are shared between all the
groups of dengue patients (Figure 2A). This could represent a
‘‘common’’ response to DENV infection, regardless of the final
clinical outcome of the patients. Surprisingly, most of these genes
appear unrelated to the immune response and instead belong
mainly to metabolism-related processes (oxidative phosphoryla-
tion, protein targeting, nucleic acid metabolism, purine and
pyrimidine metabolism, electron transport, DNA metabolism and
replication, and protein metabolism and modification) through
GO analysis (Figure 2A).
We then conducted multiple two-way SAM comparisons
between patients of different clinical classifications at a 5% false
discovery rate (Figure 2B and Table S5). There are large
differences between the acute samples taken from DF and DHF
patients relative to the DSS patients (Figure 2B). Using GO
analysis, the biological processes enriched in genes differentially
expressed by DSS patients were found to include protein
metabolism and modification, intracellular protein traffic, pre-
mRNA processing, mRNA splicing, nuclear transport, protein-
lipid modification and protein folding (Table S6 and Table S7).
While we did not identify any genes (at a 5% FDR) that were
significantly different between DF and DHF patients, a group of
neutrophil derived anti-microbial peptides (lactotransferrin, de-
fensins alpha 1,3 and 4 and cathelicidin) were among the most
highly ranked (data not shown). When we performed a sub-
analysis by grouping DF patients with severe thrombocytopenia
(platelet count of less than 50,000/mm3; ‘‘DF+’’) [[22] with DHF
patients, these genes were identified to be significantly upregulated
in the DF+/DHF patients as compared to uncomplicated DF.
Figure 1. Unsupervised hierarchical clustering analysis of
peripheral blood expression profiles from DENV-infected
individuals. (A) Gene expression patterns of peripheral blood samples
from DENV-infected patients during acute illness (3–6 days) and
convalescence as well as healthy individuals. Clustering was used to
organize genes and samples. Each row represents an individual gene
and each column an individual patient. Black indicates the median level
of expression, red indicates greater than median expression, green
depicts less than median expression, and gray indicates missing data.
Horizontal bars (labeled 1, 2 and 3) indicate the grouping of mostly DF/
DHF patients, DSS patients, and healthy/convalescent individuals,re-
spectively. (B) Principal Component Analysis (PCA) of transcriptional
profiling data. Each dot represents a DENV-infected individual plotted in
two dimensions using their projections onto the first two principal
components. Samples are coded according to clinical categories of DF,
DHF, and DSS. The circles represent clusters containing the majority
(.75%) of DSS, DF and DHF patients. (C) Reorganization of samples
based on expression values of 61 genes identified to contribute
towards the top 5% of positive variance explained by PCA2 in the
Principal Component Analysis of the dataset. Horizontal bars indicate a
cluster of DSS patients and a cluster of DF/DHF patients.
doi:10.1371/journal.pntd.0000710.g001
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As an additional strategy to determine if we could identify
candidate classification genes for different dengue patient
categories, we used multi-class SAM analysis to identify transcripts
that are up- or down-regulated among the different patient
categories (DF, DHF and DSS). At a FDR rate of less than 5%, we
identified 1525 transcripts that were differentially expressed
between the different patient categories (Table 2), including
inflammatory markers (lymphotoxin beta receptor, PRAM1,
CD14) that were more highly expressed in the DHF group.
We then used TaqMan real-time PCR primers to validate a
subset of candidate classification genes. including the group of
neutrophil-derived anti-microbial peptides that may be correlated
with DHF responses (Figure 3) We found that expression of
lactotransferrin and defensin alpha 1/3 was significantly higher in
DHF patients relative to both DF and DSS patients. PRAM1 is
down-regulated in DSS patients relative to both DHF and DF
patients, as is CD14. We also verified the expression of some
transcripts that were associated with DSS. The transmembrane
protein vezatin and the transcription factor similar to zinc finger
protein 91 were significantly up-regulated in DSS patients relative
to both DF as well as DHF patients. The transcription factor
similar to zinc finger protein 600 and the eukaryotic translation
initiation factor 1A were also significantly up-regulated in DSS
patients relative to DF patients, but not significantly different from
DHF patients.
Figure 2. Supervised comparisons between expression values
of pre-defined patient categories. (A) Venn diagram identifying
genes (n = 310) that are up-regulated in common between all
categories of DENV-infected patients relative to convalescent samples.
Up-regulated genes were identified through two-way SAM comparisons
between each group (DF, n = 20; DHF, n = 6; DSS, n = 8) and
convalescent samples (n = 6). GO analysis was used to identify
‘‘biological processes’’ significantly over-represented in this list of
‘‘common’’ genes from all DENV-infected patients. (B) Multiple two-way
SAM comparisons between patients of different clinical categories
showing the numbers of significantly up or down-regulated genes in
each comparison at a false discovery rate of 5%. Genes identified
through these two-way comparisons are listed in Table S5.
doi:10.1371/journal.pntd.0000710.g002
Table 2. Most differentially expressed genes between patient
categories.
Gene Name DF DHF DSS
ORM1-like 1 (S. cerevisiae) 20.53 21.82 2.69
transmembrane protein vezatin 20.41 21.86 2.42
dynactin 6 20.60 21.41 2.54
high mobility group nucleosomal binding domain 3 20.71 21.01 2.52
proteasome (prosome, macropain) subunit,
alpha type, 4
20.75 20.53 2.28
zinc finger protein 292 20.63 21.29 2.54
THUMP domain containing 2 20.71 20.82 2.40
similar to ribosomal protein L22 20.66 20.73 2.19
PTX1 protein 20.57 21.14 2.29
LSM8 homolog, U6 small nuclear RNA associated
(S. cerevisia
20.65 20.78 2.20
likely ortholog of mouse immediate early
response, erythrop
20.67 20.84 2.30
chromosome 14 open reading frame 112 20.71 20.62 2.23
histone acetyltransferase 1 20.66 20.70 2.17
NA 20.62 21.00 2.30
HDCMA18P protein 20.68 20.77 2.27
SUMO-1 activating enzyme subunit 2 20.53 21.20 2.23
small nuclear ribonucleoprotein polypeptide B0 20.58 21.27 2.40
PRAM-1 protein 0.44 1.41 22.16
HCV NS3-transactivated protein 1 20.67 20.75 2.24
immediate early response 3 interacting protein 1 20.55 21.03 2.16
transmembrane protein 14B 20.44 21.66 2.33
PTX1 protein 20.51 21.19 2.16
C-type lectin superfamily 2, member D 20.57 20.95 2.13
mitochondrial ribosomal protein S18C 20.70 20.53 2.14
lymphotoxin beta receptor (TNFR superfamily,
member 3)
0.22 1.88 21.95
RPA interacting protein 20.70 21.09 2.58
small nuclear ribonucleoprotein polypeptide G 20.66 20.63 2.12
CD14 antigen 0.23 1.85 21.96
RNA (guanine-9-) methyltransferase domain
containing 1
20.57 21.08 2.23
gene model 83 20.60 20.92 2.19
LSM3 homolog, U6 small nuclear RNA
associated (S. cerevisia
20.62 20.78 2.13
myoneurin 20.63 20.79 2.15
G-rich RNA sequence binding factor 1 20.71 20.86 2.41
cystatin C (amyloid angiopathy and cerebral
hemorrhage)
0.21 1.91 21.96
TatD DNase domain containing 1 20.62 20.78 2.13
zinc finger, ZZ domain containing 3 20.62 20.80 2.14
polymerase (RNA) II (DNA directed) polypeptide
K, 7.0kDa
20.43 21.47 2.17
KIAA0020 20.67 20.94 2.39
CGI-12 protein 20.65 20.90 2.30
thyroid hormone receptor interactor 3 20.66 20.65 2.12
NudC domain containing 2 20.46 21.21 2.05
Tax1 (human T-cell leukemia virus type I)
binding protein 1
20.49 21.30 2.20
programmed cell death 10 20.64 20.58 2.03
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Meta-analyses of dengue expression profiling studies
Next, we compared our results with two in vitro [13,14] and two
other in vivo studies [8,9,10] for which expression datasets are
publicly available. We searched for a ‘‘common dengue response’’
from all in vitro and in vivo studies (Table 3 and Table S8). The
biological processes that were over-represented in the up-regulated
genes were DNA replication, cell-cycle and DNA metabolism,
suggesting that DENV infection leads to an increase in the cell
cycle machinery, DNA replication and the nucleic acid metabo-
lism pathways necessary to support these processes. In contrast,
signal transduction pathways may be suppressed during DENV
infection. The immunity and defense process as well as the blood-
clotting process were also over-represented in the down-regulated
gene list.
We then examined differences between in vivo and in vitro
responses (Figure 4A). With in vivo responses, at an FDR of 0%,
1667 genes were differentially expressed, with 943 up-regulated
genes and 724 down-regulated genes (Table S9). While many
pathways and gene ontology categories were either over- or under-
represented, it was interesting to note that many of the ‘‘immune
signaling’’ categories were generally under-represented in the up-
regulated genes and over-represented in the down-regulated genes,
suggesting that DENV infection could be suppressing immune
signaling in the host. In contrast, when we examined differentially
expressed genes from the in vitro studies, we found up-regulated
genes that were over-represented in the processes of interferon-
mediated immunity, proteolysis, and immunity and defense (Table
S10). This interferon signature is not as easily observed in the in
vivo samples. When we performed a two-way comparison between
the in vitro and in vivo responses (Table S11), the biological
processes of ‘‘interferon-mediated immunity’’ and ‘‘immunity and
defense’’ were again over-represented in the upregulated genes
from the in vitro studies, consistent with the observation of an
Gene Name DF DHF DSS
TatD DNase domain containing 1 20.60 20.80 2.11
KIAA0776 20.43 21.20 1.98
NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 3, 12kDa
20.73 20.22 1.99
dolichyl-phosphate mannosyltransferase
polypeptide 1, catal
20.68 20.49 2.07
similar to ribosomal protein L22 20.69 20.29 1.94
cyclin C 20.35 21.36 1.90
translocase of inner mitochondrial membrane 17
homolog A (y
20.55 20.99 2.11
ubiquitin carboxyl-terminal esterase L3 (ubiquitin
thiolest
20.63 20.90 2.25
transposon-derived Buster1 transposase-like
protein gene
20.61 20.81 2.13
heat shock 10kDa protein 1 (chaperonin 10) 20.48 21.17 2.08
eukaryotic translation initiation factor 3, subunit 6
48kDa
20.33 21.65 2.06
proteasome (prosome, macropain) 26S subunit,
ATPase, 6
20.60 20.69 2.03
similar to bA486O22.3 (similar to RPS3A
(ribosomal protein
20.58 20.82 2.07
proteasome (prosome, macropain) subunit,
alpha type, 3
20.59 20.80 2.08
baculoviral IAP repeat-containing 2 20.61 20.76 2.10
chondroitin sulfate proteoglycan 6 (bamacan) 20.56 20.98 2.13
KIAA1040 protein 20.64 20.74 2.15
Rab geranylgeranyltransferase, beta subunit 20.41 21.33 2.02
dolichyl-phosphate mannosyltransferase
polypeptide 1, catal
20.61 20.73 2.08
solute carrier family 43, member 2 0.46 1.25 22.09
mitochondrial ribosomal protein L32 20.61 20.75 2.09
caspase recruitment domain family, member 9 0.15 2.07 21.92
ATP-binding cassette, sub-family E (OABP), member 1 20.49 21.11 2.07
CD68 antigen 0.04 2.07 21.65
tubulin-specific chaperone a 20.50 21.14 2.10
EPM2A (laforin) interacting protein 1 20.05 22.29 1.84
nucleolar protein 8 20.52 21.34 2.30
kinectin 1 (kinesin receptor) 20.52 21.10 2.13
activated RNA polymerase II transcription cofactor 4 20.49 21.00 1.96
COP9 constitutive photomorphogenic homolog
subunit 4 (Arabi
20.59 20.91 2.16
heat shock 10kDa protein 1 (chaperonin 10) 20.56 20.93 2.09
chromosome 21 open reading frame 66 20.61 20.87 2.18
apolipoprotein B48 receptor 0.35 1.48 21.99
peptidyl-prolyl isomerase G (cyclophilin G) 20.59 20.88 2.13
pinin, desmosome associated protein 20.66 20.66 2.14
heat shock 70kDa protein 14 20.59 20.78 2.06
jumonji domain containing 3 0.26 1.72 21.95
hemoglobin, alpha 1 0.30 1.46 21.83
hypothetical protein MGC5509 20.52 21.11 2.13
mitochondrial ribosomal protein L47 20.64 20.57 2.02
mitochondrial ribosomal protein L1 20.57 20.81 2.02
cylindromatosis (turban tumor syndrome) 20.80 20.44 2.33
Table 2. Cont.
Gene Name DF DHF DSS
stress-associated endoplasmic reticulum protein 1 20.48 21.10 2.03
lectin, galactoside-binding, soluble, 9 (galectin 9) 0.14 2.09 21.91
zinc finger, DHHC domain containing 17 20.56 20.92 2.10
hypothetical protein DKFZp586C1924 20.67 20.51 2.06
dolichyl-phosphate mannosyltransferase
polypeptide 1, catal
20.60 20.65 2.00
proteasome (prosome, macropain) subunit,
alpha type, 2
20.67 20.65 2.17
mitochondrial ribosomal protein L13 20.49 21.00 1.98
DnaJ (Hsp40) homolog, subfamily A, member 1 20.84 20.19 2.23
TGF beta-inducible nuclear protein 1 20.69 20.59 2.17
solute carrier family 35 (CMP-sialic acid
transporter), mem
20.61 20.85 2.17
Sjogren syndrome antigen B (autoantigen La) 20.76 20.37 2.18
source of immunodominant MHC-associated peptides 20.47 21.06 1.97
metaxin 3 20.51 21.06 2.07
likely ortholog of mouse hypoxia induced gene 1 20.58 20.76 2.03
thioredoxin domain containing 10 20.55 20.86 2.02
Values shown represent the contrast value for each gene. This is the
standardized mean difference between the gene’s expression in that class,
versus its overall mean expression.
doi:10.1371/journal.pntd.0000710.t002
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interferon signature in in vitro DENV infection, which was stronger
than that observed in in vivo patient samples. For the 156 genes
more highly expressed in the in vivo samples, purine metabolism
was again over-represented and signal transduction was under-
represented, supporting the hypothesis that there is an increase in
nucleic acid metabolism and a suppression of signaling in the
peripheral blood cells of dengue patients.
Finally, we compared severe versus non-severe dengue cases in
the integrated dengue patient dataset, which includes the
Nicaraguan patients in our study and the Vietnamese patients in
the Simmons and Long studies [9,10]. At a FDR of 0%, 32 genes
were significantly different between the two groups, with 25 genes
more highly expressed in severe patients and 7 genes more highly
expressed in the non-severe patients (Figure 4B and Table S12).
Among the genes up-regulated in severe dengue patients are
transcription factors that belong to the Kruppel-like factor family
(KLF9 and KLF12), which have mainly been studied in the
context of development. Galectin 9, a Tim-3 ligand, is down-
regulated in severe dengue patients.
We were surprised that genes involved in type I interferon
production were not more highly represented from the in vivo
studies, hence we extracted the expression data of 24 genes that
are well-characterized as components of the type I IFN signature
(Figure 5). While the expression of these genes are clearly up-
regulated in DF patients and suppressed in DSS patients as
described in the Long et al. study [9], this pattern is less obvious
from the Nicaragua dataset, as well as from the Simmons et al.
study [10].
Discussion
In this study, we found that DENV infection in vivo is
characterized by upregulation of metabolic genes involved in
nucleic acid and protein metabolism. We also observed a clear
distinction in transcriptional profiles between shock-associated
DENV infection relative to infection that led to DHF or DF,
characterized mainly by an increased expression of mitochon-
drial ribosomal proteins. We also found a group of neutrophil-
derived anti-microbial peptides (lactotransferrin and defensin
A1/A3) up-regulated in DHF patients. Finally, by integrating
our dataset with other datasets, we confirmed our observations
that genes involved in nucleic acid metabolism are up-regulated
during in vivo infection. These results suggest that DENV
infection leads to large changes in the metabolic pathways of
peripheral blood cells.
Why are metabolic pathways upregulated in the peripheral
blood during DENV infection in vivo? One possibility is that
DENV infection induces a strong B cell proliferative response,
since there was also an over-representation of immunoglobulin
transcripts and protein trafficking categories. Simmons et al. [10]
have previously noted an abundance of proliferating B cell
plasmablasts that may be associated with the increased expression
of genes involved in cell cycle control. Notably, IRF4 and BLNK
expression are strongly represented in the in vivo meta-analysis,
supporting the hypothesis that B cell stimulation, proliferation and
differentiation may be a feature of acute DENV infection. It is
possible that this signature is further amplified during severe
manifestations of dengue, since many genes involved in protein
biosynthesis (such as the ribosomal proteins) are further up-
regulated, which could be a result of increased antibody
production. Another possibility could be the activation of an
integrated stress response. It was previously found that expression
signatures related to the endoplasmic reticulum (ER) are elevated
during acute DENV infection, suggesting the induction of ER
stress [10]. The results from both the Nicaragua dataset, as well as
our meta-analysis of the integrated dataset, support this hypoth-
esis. Activation of this integrated stress response has also been
noted through a systems biology analysis of the yellow fever
vaccine [23], as well as in Japanese encephalitis virus- and DENV-
2-infected cells [24].
The greater difference observed between DSS versus DF and
DHF patients supports the concept of dengue as a spectrum of
disease severity, with severe disease characterized by shock
[Dengue guidelines for diagnosis, treatment, prevention and
control. Third Edition 2009. WHO, Geneva]. The most dramatic
changes that occur during severe dengue with shock appear to be
effects on cellular physiology rather than on immune responses.
Increased expression of mitochondrial ribosomal proteins may be
an indication that protein biosynthesis could be ramped up in DSS
patients. Understanding why protein biosynthesis may be
increased in DSS patients requires further studies. Increased viral
replication and viral load [25] and slower rates of viral clearance
[26] have been associated with severe manifestations of dengue. It
is possible that the increased signature of protein biosynthesis is
related to increased production of viral proteins; however, DENV
viral load is usually declining by 3–6 days of illness. In addition to
protein synthesis, there are many unknown functions of ribosomal
proteins [27,28,29]. For example, L13a is involved in IFN-g-
mediated translational inhibition in human monocytes [30]. A
better understanding of the relationship between ribosomal
Figure 3. Verification of gene expression by real-time PCR analysis of DENV-infected patient peripheral blood samples. Transcript
levels of selected genes were measured and normalized to b-actin transcript levels. Horizontal bars indicate median expression levels. Statistical
significance between groups were determined by the 2-tailed Mann-Whitney test. A p value of ,0.05 is indicated by *; p,0.01 is indicated by **, and
p,0.001 is indicated by ***. In some cases, transcripts were below the detection limit, as indicated by the horizontal bar (nd).
doi:10.1371/journal.pntd.0000710.g003
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Table 3. Top 100 ‘‘Common dengue response’’ up-regulated
genes identified through a meta-analysis of in vitro and in vivo
transcriptional profiling studies.
Gene ID Gene Name Score(d)
3071 (DUSP5) dual specificity phosphatase 5 7.08
1508 (CASP7) caspase 7, apoptosis-related cysteine peptidase 5.92
3527 (EZH2) enhancer of zeste homolog 2 (Drosophila) 5.61
1667 (CD38) CD38 molecule 5.39
20090 (DNAJC1) DnaJ (Hsp40) homolog, subfamily C, member 1 5.36
2000 (CKS2) CDC28 protein kinase regulatory subunit 2 5.33
1132 (BTG3) BTG family, member 3 5.14
20461 (NME7) non-metastatic cells 7, protein expressed in
(nucleoside-diphosphate kinase)
5.13
2347 (CREB3) cAMP responsive element binding protein 3 5.09
8907 (PGM3) phosphoglucomutase 3 5.05
12311 (TRIP6) thyroid hormone receptor interactor 6 4.85
10702 (SEC23B) Sec23 homolog B (S. cerevisiae) 4.82
1176 (MRPL49) mitochondrial ribosomal protein L49 4.81
10703 (SEC24A) SEC24 family, member A (S. cerevisiae) 4.71
4162 (GARS) glycyl-tRNA synthetase 4.71
9569 (PSME2) proteasome (prosome, macropain) activator
subunit 2 (PA28 beta)
4.71
6948 (MCM5) minichromosome maintenance complex
component 5
4.71
17895 (UBE2S) ubiquitin-conjugating enzyme E2S 4.70
21348 (MLF1IP) MLF1 interacting protein 4.69
2718 (DDB2) damage-specific DNA binding protein 2, 48kDa 4.67
1148 (BUB1) budding uninhibited by benzimidazoles
1 homolog (yeast)
4.64
18643 (SF4) splicing factor 4 4.62
20144 (ZNF410) zinc finger protein 410 4.61
3650 (FEN1) flap structure-specific endonuclease 1 4.59
18538 (NUSAP1) nucleolar and spindle associated protein 1 4.59
11302 (SRP68) signal recognition particle 68kDa 4.55
6388 (KIF11) kinesin family member 11 4.48
7397 (MT1E) metallothionein 1E 4.42
1745 (CDC7) cell division cycle 7 homolog (S. cerevisiae) 4.41
1504 (CASP3) caspase 3, apoptosis-related cysteine peptidase 4.41
92 (ACADVL) acyl-Coenzyme A dehydrogenase, very long
chain
4.40
10451 (RRM1) ribonucleotide reductase M1 4.37
17943 (DERL2) Der1-like domain family, member 2 4.32
7398 (MT1F) metallothionein 1F 4.31
17598 (UBE2J1) ubiquitin-conjugating enzyme E2, J1 (UBC6
homolog, yeast)
4.31
6395 (KPNA2) karyopherin alpha 2 (RAG cohort 1,
importin alpha 1)
4.31
14938 (PIGT) phosphatidylinositol glycan anchor biosynthesis,
class T
4.29
15832 (BSCL2) Bernardinelli-Seip congenital lipodystrophy 2
(seipin)
4.29
17493 (GMNN) geminin, DNA replication inhibitor 4.27
17064 (ELL2) elongation factor, RNA polymerase II, 2 4.26
7693 (NDUFA9) NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 9, 39kDa
4.25
Gene ID Gene Name Score(d)
4716 (HIST1H1C) histone cluster 1, H1c 4.25
10044 (RNASE1) ribonuclease, RNase A family, 1 (pancreatic) 4.25
29608 (MTDH) metadherin 4.24
9226 (PPA1) pyrophosphatase (inorganic) 1 4.21
17981 (RTCD1) RNA terminal phosphate cyclase domain 1 4.21
25009 (UBE2T) ubiquitin-conjugating enzyme E2T (putative) 4.20
1739 (CDC45L) CDC45 cell division cycle 45-like (S. cerevisiae) 4.19
20038 (DDX52) DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 4.18
17357 (APOBEC3G) apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 3G
4.17
25585 (OGFOD1) 2-oxoglutarate and iron-dependent
oxygenase domain containing 1
4.14
19071 (THOC4) THO complex 4 4.11
9972 (RFC4) replication factor C (activator 1) 4, 37kDa 4.10
952 (BARD1) BRCA1 associated RING domain 1 4.09
1082 (BNIP1) BCL2/adenovirus E1B 19kDa interacting protein 1 4.08
11300 (SRP19) signal recognition particle 19kDa 4.08
13266 (DDX24) DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 4.08
949 (BAK1) BCL2-antagonist/killer 1 4.07
17022 (HPS5) Hermansky-Pudlak syndrome 5 4.06
11913 (TNFRSF17) tumor necrosis factor receptor superfamily,
member 17
4.03
8729 (PCNA) proliferating cell nuclear antigen 4.02
9316 (PPP3CC) protein phosphatase 3 (formerly 2B), catalytic
subunit, gamma isoform
4.02
13870 (NUDT21) nudix (nucleoside diphosphate linked
moiety X)-type motif 21
4.00
16870 (MELK) maternal embryonic leucine zipper kinase 3.98
372 (AKAP2) A kinase (PRKA) anchor protein 2 3.98
28351 (C11orf48) chromosome 11 open reading frame 48 3.98
7406 (MT2A) metallothionein 2A 3.96
3245 (EHD4) EH-domain containing 4 3.96
16429 (LIAS) lipoic acid synthetase 3.95
23115 (EAF2) ELL associated factor 2 3.95
5384 (IDH3A) isocitrate dehydrogenase 3 (NAD+) alpha 3.94
13813 (SLC4A1AP) solute carrier family 4 (anion exchanger),
member 1, adaptor protein
3.94
16065 (GLRX2) glutaredoxin 2 3.93
20320 (PSPC1) paraspeckle component 1 3.93
6947 (MCM4) minichromosome maintenance complex
component 4
3.91
10381 (RPN1) ribophorin I 3.91
1580 (CCNB2) cyclin B2 3.88
1578 (CCNA2) cyclin A2 3.87
9548 (PSMC2) proteasome (prosome, macropain) 26S
subunit, ATPase, 2
3.87
4248 (GGH) gamma-glutamyl hydrolase (conjugase,
folylpolygammaglutamyl hydrolase)
3.85
9343 (PRCC) papillary renal cell carcinoma (translocation-
associated)
3.85
12417 (TUBG1) tubulin, gamma 1 3.85
17557 (LCMT1) leucine carboxyl methyltransferase 1 3.85
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proteins and DENV infection and shock syndrome requires
additional investigation. The shock-associated genes that we
observed have not been noted in other transcriptional profiling
studies of children with septic shock [31]. In those studies, shock
was associated with down-regulation of genes involved in zinc-
related biology and adaptive immunity [31]. This is not surprising,
since dengue shock is a very different clinical entity from septic
shock [1].
While the commonly observed interferon signature from in vitro
host-pathogen expression profiling studies is also observed with
our meta-analysis of in vitro DENV infection, this signature is not
consistently observed from in vivo patient samples in all studies.
Except for CD38, we did not identify many immune-related genes,
or genes involved in IFN signaling from DENV infection in the
Nicaragua study. This is most likely due to the dynamic nature of
acute DENV infection. Unfortunately, accurate defervescence
data was not available for all of these study samples collected in
2003–2004, which meant it was not possible to relate the
transcriptionl profiles with timing of defervescence. Future
longitudinal sampling studies will be needed to examine more
closely the dynamic nature of changes in transcriptional profiles
over time. From a clinical perspective, our convalescent samples
were collected approximately two weeks after symptom onset, as
compared to the convalescent samples by Long et al. [9] which
were collected at the one month follow-up visit. In our case, the
IFN-driven immune response may not have subsided, which
would mask the differences in our convalescence comparisons.
However, it should be noted that most of our convalescent samples
still cluster with the samples collected from healthy volunteers
(Figure 1A), indicating that they are more similar to uninfected
individuals than to acutely infected individuals. Another limitation
of this study is that we did not collect sufficient convalescent
samples to make autologous comparisons. This may influence the
identification of differentially expressed genes between acute and
convalescent samples. The explanation we favor for the difference
between our study and the study by Long et al. [9] is that the IFN
responsive genes are expressed very early and transiently during
acute DENV infection. The Nicaragua study and the earlier
Simmons et al. [10] study contained samples that were collected
1–2 days later during the infection cycle than in the Long et al. [9]
study, and this difference may well explain the lack of IFN
response genes observed in the former studies. The manifestations
of DENV infection could also be different between Southeast
Asian populations in comparison to the Nicaraguan population
that we characterized. Lastly, infection by different circulating
DENV serotypes could also contribute to differences in host
response.
We noted with interest that Long et al. [9] also observed a
significantly higher expression of LTF, DEFA3 and DEFA4 in
patient samples with DSS [9]. We found that LTF and DEFA1
were up-regulated in DHF patients but not in DSS patients.
Nonetheless, expression of this group of anti-microbial peptides is
clearly associated with clinical manifestations more severe than
uncomplicated DF. Lactotransferrin (or lactoferrin), cathelicidin
(or LL-37) and the defensins are all present in mucosal secre-
tions, are produced at high levels by neutrophils, and have all
been shown to have antiviral (especially anti-HIV) activity
[32,33,34,35,36]. Since nothing is known about the role of these
molecules in DENV infection, further studies should explore their
functions in pathogenesis or anti-DENV immunity.
We also noted that CD14 was up-regulated in DHF patients
relative to both DF and DSS patients. This was consistent with the
study by de Kruif et al. [37], who found that CD14 was down-
regulated in Indonesian children with DSS, relative to DF and
DHF cases. CD14 was also down-regulated in DSS patients from
Vietnam [10]. CD14 is a monocyte marker and monocytes (as well
as macrophages) are known to be the major target cells for DENV
infection [38] in patients [39,40,41] as well as in mouse models
[42]. Further transcriptional profiling efforts focused on this
population of cells may reveal interesting mechanisms of
pathogenesis.
Accurate gene expression profiling of peripheral blood is
challenging because isolating peripheral blood mononuclear cells
(PBMCs) by density gradient centrifugation can interfere with
biological signatures, especially if the timing between the blood
draw and cell isolation is variable [43]. While PAXgene tubes
greatly reduce the time between blood draw and RNA
stabilization, they introduce abundant globin mRNA that may
interfere also with biological signatures [44,45]. In this study, we
used PAXgene tubes in combination with a globin removal system
to reduce interference as much as possible. Unlike profiling
PBMCs, PAXgene tubes include the transcriptional signatures of
reticulocytes, neutrophils and other polymorphonuclear (PMN)
cells, hence there are likely to be differences between profiling
studies of PBMCs relative to PAXgene samples. For example, the
differences in expression of neutrophil-derived anti-microbial
peptides would probably not be observed in PBMC studies.
A diagnostic assay that can assist clinicians assess the relative
risk of patients progressing towards severe forms of the disease
would be a very powerful tool for clinical management. Earlier
sampling than was conducted in this study may be required to
identify markers for such an assay. Although none of the
transcriptional profiling studies that have been conducted so far
Gene ID Gene Name Score(d)
7548 (MYBL2) v-myb myeloblastosis viral oncogene homolog
(avian)-like 2
3.84
7434 (MTHFD2) methylenetetrahydrofolate dehydrogenase
(NADP+ dependent) 2, methenyltetrahydrofolate
cyclohydrolase
3.83
12718 (VRK1) vaccinia related kinase 1 3.83
10942 (SLC1A4) solute carrier family 1 (glutamate/neutral
amino acid transporter), member 4
3.81
14211 (BLNK) B-cell linker 3.81
19123 (DNAJC9) DnaJ (Hsp40) homolog, subfamily C, member 9 3.79
18967 (EDEM1) ER degradation enhancer, mannosidase
alpha-like 1
3.79
5978 (IL15RA) interleukin 15 receptor, alpha 3.78
10706 (SEC24D) SEC24 family, member D (S. cerevisiae) 3.78
6949 (MCM6) minichromosome maintenance complex
component 6
3.76
1101 (BRCA2) breast cancer 2, early onset 3.73
6130 (ISG20) interferon stimulated exonuclease gene 20kDa 3.73
9537 (PSMB1) proteasome (prosome, macropain) subunit,
beta type, 1
3.72
2993 (DONSON) downstream neighbor of SON 3.72
9532 (PSMA3) proteasome (prosome, macropain) subunit,
alpha type, 3
3.71
12719 (VRK2) vaccinia related kinase 2 3.70
9356 (PREB) prolactin regulatory element binding 3.69
10535 (SAR1B) SAR1 homolog B (S. cerevisiae) 3.69
doi:10.1371/journal.pntd.0000710.t003
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can claim to have identified genes that have been validated for
prognostic potential, it is conceivable that in the near future we
can combine datasets from multiple studies through the type of
meta-analysis that we have initiated here to identify candidate
genes that can then be tested independently in other clinical
studies, perhaps at multiple sites. As additional data becomes
available, such a dengue pathogenesis assay, based on clinical
markers and expression profiles of a few prognostic genes may
become closer to reality.
Supporting Information
Figure S1 Principal Component Analysis of transcriptional
profiling data. (A) Plot showing the amount of variance (on the
Y-axis) that is explained by each of the principal components
(PCA). The results show that the first two principal components
(PCA1 and PCA2) contribute the most towards the total variance.
(B) Scatterplot of the eigenvector values for principal component 2
for dengue infected individuals. The results show that the values
for PCA2 are significantly greater in the DSS patients. (C)
Histogram showing the genes identified as contributing towards
the top 5% of the positive variance explained by PCA2. (D)
Reclustering of samples based on the expression values of 90 genes
identified to be the top 5% of genes that are positively correlated
with PCA2 (out of N=1832). (E) Gene Ontology analysis of the 90
genes described above showing the biological processes that are
over-represented by these genes.
Found at: doi:10.1371/journal.pntd.0000710.s001 (0.76 MB PDF)
Table S1 Gene Ontology (GO) analysis of the biological
processes and molecular functions that are over-represented by a
set of 61 genes that could be related to shock because they
contribute towards the top 5% of the positive variance explained
by PCA2.
Found at: doi:10.1371/journal.pntd.0000710.s002 (0.01 MB XLS)
Table S2 Identification of genes that are significantly upregu-
lated in acute DF samples relative to convalescent samples by two-
way supervised comparisons using SAM.
Figure 4. Meta-analyses of integrated DENV expression profiling datasets. (A) Comparison between in vitro profiling studies of DENV-
infected cells and in vivo profiling studies of DENV-infected patients. Each row represents an individual gene and each column an averaged value
from the different studies. Black indicates the median level of expression, red indicates greater than median expression, green indicates less than
median expression, and gray represents missing data. A subset of genes that are prominently up-regulated in either the in vitro or in vivo studies are
listed. (B) Identification of 32 genes that are significantly different between severe (S; DSS) and non-severe (NS; DF & DHF) dengue cases through a
meta-analysis of Vietnamese and Nicaraguan patients. Twenty-five genes were more highly expressed in severe patients (red vertical bar) and 7 genes
were more highly expressed in non-severe patients (blue vertical bar). The horizontal bar indicates the respective studies (Loke, Long and Simmons)
and classification of the patients as severe (S; DSS) or non-severe (NS; DF&DHF).
doi:10.1371/journal.pntd.0000710.g004
Figure 5. Expression of 24 IFN-upregulated genes in the meta-
analysis of dengue patients. Each row represents an individual gene
and each column the value from an individual patient from the different
studies. Black indicates the median level of expression, red indicates
greater than median expression, green indicates less than median
expression, and gray represents missing data. The horizontal bar
denotes the respective studies (Loke, Long and Simmons) and
classification of the patients as severe (S; DSS) or non-severe (NS;
DF&DHF).
doi:10.1371/journal.pntd.0000710.g005
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Found at: doi:10.1371/journal.pntd.0000710.s003 (0.10 MB XLS)
Table S3 Identification of genes that are significantly upregu-
lated in acute DHF samples relative to convalescent samples by
two-way supervised comparisons using SAM.
Found at: doi:10.1371/journal.pntd.0000710.s004 (0.07 MB XLS)
Table S4 Identification of genes that are significantly upregu-
lated in acute DSS samples relative to convalescent samples by
two-way supervised comparisons using SAM.
Found at: doi:10.1371/journal.pntd.0000710.s005 (0.11 MB XLS)
Table S5 Identification of genes that are significantly different
between patients of different clinical classifications by two-way
supervised comparisons using SAM.
Found at: doi:10.1371/journal.pntd.0000710.s006 (0.03 MB XLS)
Table S6 Gene Ontology (GO) analysis of the biological
processes and molecular functions that are overrepresented by
genes identified to be differentially expressed between acute DF
and DSS samples.
Found at: doi:10.1371/journal.pntd.0000710.s007 (0.02 MB XLS)
Table S7 Gene Ontology (GO) analysis of the biological
processes and molecular functions that are overrepresented by
genes identified to be differentially expressed between acute DHF
and DSS samples.
Found at: doi:10.1371/journal.pntd.0000710.s008 (0.01 MB XLS)
Table S8 Identification of a set of ‘‘common dengue response’’
genes for both in vitro and in vivo transcriptional profiling studies
through a meta-analysis of 5 separate studies. Genes upregulated
by DENV infection are shown in red and genes downregulated are
shown in green.
Found at: doi:10.1371/journal.pntd.0000710.s009 (0.50 MB XLS)
Table S9 Identification of genes that are significantly different
from in vivo transcriptional profiling studies that have been
conducted previously through a meta-analysis of 3 separate
studies. Genes upregulated by DENV infection are shown in red
and genes downregulated are shown in green.
Found at: doi:10.1371/journal.pntd.0000710.s010 (1.66 MB XLS)
Table S10 Identification of genes that are significantly different
from in vitro transcriptional profiling studies that have been
conducted previously through a meta-analysis of 2 separate
studies. Only upregulated genes were found in this analysis.
Found at: doi:10.1371/journal.pntd.0000710.s011 (0.06 MB
XLS)
Table S11 Identification of genes that significantly different
between in vitro and in vivo studies by two-way comparisons
through meta-analysis. Genes that are relatively upregulated in in
vitro studies are shown in red and genes that are relatively
upregulated in in vivo studies are shown in green.
Found at: doi:10.1371/journal.pntd.0000710.s012 (0.30 MB
XLS)
Table S12 Identification of genes that are significantly different
between severe (DSS) versus non severe (Df and DHF) cases
through a meta-analysis of 3 separate studies. Genes upregulated
in severe DSS patients are shown in red and genes more highly
expressed in non severe DF/DHF patients are shown in green.
Found at: doi:10.1371/journal.pntd.0000710.s013 (0.05 MB
XLS)
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